Response: Re: Marketing Messages in Continuing Medical Education (CME) Modules on Binge-Eating Disorder (BED)

References

1. 1.↵
   1. Bulik CM,
   2. Keck PE,
   3. McElroy SL,
   4. Vega CP

   . Recent advances in the management of binge eating disorder. March 26, 2014. Available from: https://www.medscape.org/viewarticle/821956?src=wnl_cme_revw.
2. 2.↵
   1. McElroy SL

   . Assessing the impact of binge eating disorder: focus on your practice. December 26, 2013. http://www.medscape.org/viewarticle/818103.
3. 3.↵
   1. McElroy SL,
   2. Vega CP

   . Improving the management of binge eating disorder: a collaborative treatment approach. September 2, 2014. Available from: http://www.medscape.org/viewarticle/830450_transcript.
4. 4.↵
   1. Spyropoulos J,
   2. Chatterjee P,
   3. Desai J,
   4. Vega C

   . Effectiveness of online CME in improving knowledge and awareness related to emerging management approaches for binge-eating disorder (poster). Available from: https://img.medscapestatic.com/pi/edu/qrcode/posters/effectiveness-of-online-cme-for-binge-eating-disorder.pdf Accessed July 8, 2020.
5. 5.↵
   Vyvanse. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208510lbl.pdf.
6. 6.↵
   1. Citrome L

   . Test your knowledge of challenging cases in eating disorders. February 23, 2016. Available from: https://www.medscape.org/viewarticle/855587.
7. 7.↵
   1. Lubarda J,
   2. Chatterjee P,
   3. Citrome L

   . Binge eating disorder management: can medical education improve physician knowledge? (poster). Available from: https://img.medscapestatic.com/pi/edu/qrcode/posters/binge-eating-disorder-management-can-medical-education-improve-physician-knowledge.pdf. Accessed July 8, 2020.
8. 8.↵
   FDA Guidance document: industry-supported scientific and educational activities. December 1997. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/industry-supported-scientific-and-educational-activites. Accessed July 10, 2020.
9. 9.↵
   1. Fugh-Berman A,
   2. Hogenmiller A

   . CME stands for commercial medical education: and ACCME still won't address the issue. J Med Ethics 2016;42:172–3.

   OpenUrlFREE Full Text
10. 10.↵
    1. Meixel A,
    2. Yanchar E,
    3. Fugh-Berman A

    . Hypoactive sexual desire disorder: inventing a disease to sell low libido. J Med Ethics 2015;41:859–62.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Infeld M,
    2. Bell A,
    3. Marlin C,
    4. et al

    . Continuing medical education and the marketing of fentanyl for breakthrough pain: marketing messages in an industry‐funded CME module on breakthrough pain. World Med Health Pol 2019;11:43–58.

    OpenUrl
12. 12.↵
    1. Jung J,
    2. Fug-Berman A

    . Marketing messages in continuing medical education (CME) modules on binge-eating disorder (BED). J Am Board Fam Med 2020;33:240–51.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Dieperink ML,
    2. Drogemuller L

    . Industry-sponsored grand rounds and prescribing behavior. JAMA 2001;285:1443–4.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Orlowski JP,
    2. Wateska L

    . The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. Chest 1992;102:270–3.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Bowman MA,
    2. Pearle DL

    . Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof 1988;8:13–20.

    OpenUrlCrossRefPubMed